The CYT1 isoform of HER4 (an epidermal growth factor receptor (EGFR) family member) inhibits cell growth and proliferation in breast cancer, suggesting that it could influence cancer sensitivity to Her-targeting treatment modalities. This evidence concerns the gene ERBB4 and breast carcinoma.